FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
34 letters match. Newest first.
-
BiologicsCalibrate IV Hydration
FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.
High risk -
BiologicsBeaute Bounty
FDA warns Beaute Bounty that its stem cell and placenta products are unapproved drugs and unlicensed biologics.
High risk -
BiologicsBlue Horizon International, LLC
FDA warned Blue Horizon International over unapproved stem cell and exosome biologics marketed for serious diseases without a license.
High risk -
BiologicsDynamic Stem Cell Therapy
FDA warned Dynamic Stem Cell Therapy that its umbilical cord-derived stem cell product is an unapproved, unlicensed, misbranded biological drug.
High risk -
BiologicsMicrovascular Tissue, Inc.
FDA says Microvascular Tissue's mVASC wound product is an unapproved drug and unlicensed biologic, made without validated processes.
High risk -
BiologicsLux Therapeutics LLC dba Ponya Therapeutics LLC
FDA warns Lux Therapeutics over unvalidated TheraMend amniotic patches and records, citing inadequate response and Luxegen distribution concerns.
High risk -
BiologicsAllovate Therapeutics, LLC
FDA warned Allovate that its Allerdent allergenic toothpaste is an unapproved drug and lacks a required biologic license.
High risk -
BiologicsNew Life Medical Services, LLC
FDA says New Life Medical Services sells unapproved umbilical-cord, amniotic-fluid, and exosome products as drugs.
High risk -
BiologicsCellebration LLC
FDA warns Cellebration LLC over unapproved cord-blood cellular products and refusal to provide requested records.
High risk -
BiologicsPlatinum Biologics LLC
FDA says Platinum Biologics sells unapproved umbilical cord and exosome biologics without required licenses or approvals.
High risk -
BiologicsMG Infusions
FDA warned MG Infusions it sells unlicensed fecal transplant products online without required approval.
High risk -
BiologicsChara Biologics, Inc.
FDA warns Chara Biologics over unapproved, unlicensed CharaExo, CharaCore, CharaOmni.
High risk -
BiologicsEvolutionary Biologics Inc.
FDA warned Evolutionary Biologics that its exosome and umbilical-cord products are unapproved new drugs and unlicensed biologics sold with disease-treatment claims.
High risk -
BiologicsPinnacle Transplant Technologies, LLC
FDA warns Pinnacle Transplant Technologies over unapproved injectable amniotic products and sterility CGMP failures.
High risk -
BiologicsMother Stem Institute, Corp.
FDA warns Mother Stem Institute over unapproved fat-derived SVF 'stem cell' biologic marketed for serious diseases.
High risk -
BiologicsBerkeley Biologics, LLC, previously operating as Elutia, Inc. – Orthobiologics Business Unit, formerly Aziyo Biologics, Inc.
FDA says Berkeley Biologics' viable bone matrix products are unapproved drugs, with donor screening failures tied to tuberculosis infections.
High risk -
BiologicsNeobiosis, LLC
FDA warns Neobiosis over unapproved amniotic fluid and umbilical cord products and serious manufacturing quality failures.
High risk -
BiologicsHuman Microbes
FDA warned Human Microbes that selling fecal microbiota for transplantation as an unapproved drug and unlicensed biologic lacks required BLA or IND.
High risk -
BiologicsMiMedx Group, Inc.
FDA cites MiMedx for marketing placental product AXIOFILL without BLA or IND and for CGMP failures.
High risk -
BiologicsKimera Labs, Inc.
FDA warns Kimera Labs over unapproved exosome and amniotic fluid products and serious sterile manufacturing failures.
High risk -
BiologicsAbbott Laboratories
FDA warns Abbott that Similac Probiotic Tri-Blend for preterm infants is an unapproved drug and adulterated supplement.
High risk -
BiologicsInfinant Health, Inc formerly Evolve Biosystems Inc.
FDA says Infinant Health's Evivo with MCT Oil probiotic is an unapproved biologic drug and unsafe food additive for preterm infants.
High risk -
BiologicsSignature Biologics, LLC
FDA cited Signature Biologics for unapproved, unlicensed Signature Cord and serious sterile manufacturing failures.
High risk -
BiologicsRenatiLabs Inc.
RenatiLabs marketed WJMAX, a human umbilical cord-derived biologic, without a license and released a lot that failed sterility testing.
High risk -
BiologicsStratus Biosystems, LLC dba CellGenuity Regenerative Science
FDA warns CellGenuity over unapproved amniotic/umbilical products and serious sterility failures.
High risk -
BiologicsInvitrx Therapeutics, Inc.
Invitrx Therapeutics made unapproved umbilical cord and exosome products and had serious manufacturing deviations.
High risk -
DrugsSovereign Pharmaceuticals, LLC
FDA cited Sovereign Pharmaceuticals for manufacturing failures in bulk tablets, inadequate out-of-specification (OOS) investigations, quality-unit lapses, and an unapproved biological product.
High risk -
BiologicsBioLab Sciences, Inc.
FDA warned BioLab Sciences that its injected amniotic fluid and skin products were unapproved biologics with serious manufacturing violations.
High risk -
BiologicsVitti Labs, LLC
FDA warns Vitti Labs over unapproved umbilical cord and amniotic membrane products and sterile manufacturing failures.
High risk -
BiologicsRe-Gen Active Lab, Inc.
FDA warned Re-Gen Active Lab over unapproved amniotic/umbilical cord injectables and serious sterility failures.
High risk -
BiologicsSmart Surgical, Inc dba Burst Biologics
Burst Biologics distributed unapproved umbilical cord blood products as drugs while failing sterility and donor-screening rules.
High risk -
BiologicsSurgenex LLC
FDA warned Surgenex it sold unapproved umbilical cord and amniotic membrane products for injection without a biologics license and with serious manufacturing problems.
High risk -
BiologicsUtah Cord Bank LLC dba Utah Cell Bank
Utah Cell Bank made unapproved injectable stem cell products and fell short on sterility and manufacturing controls, FDA found.
High risk -
DrugsAllay Pharmaceuticals, LLC
FDA warned Allay Pharmaceuticals over CGMP failures and sub-potent tablets, and distribution of an unapproved biological product.
High risk